Researchers found stem cells in the ovaries of young women that have the potential to become healthy eggs. Applications of this discovery may help women have children that were once too old to or left infertile because of disease.
Natalie Melgar-Fetzer, a junior in ICS from Maryland said “It’s interesting because it can give women with reproductive problems the opportunity to have children. So many people want to have babies but can’t for whatever reason.”
Researchers have already created potentially viable eggs from these stem cells by adding a protein to them as well as a gene that makes jellyfish glow
The use of stem cells has often been a controversial issue in the media. International Stem Cell Corp. looks set to tackle the issue head on after launching its own line of stem cell based beauty products. According to reports online the skin care range was created by its wholly owned subsidiary Lifeline Skin Care.
CEO of Lifeline Skin Care, Dr. Ruslan Semechkin, was quoted as saying, “The commercial launch of the new skin care products represents an important step in the execution of ISCO`s strategy.” Plastic surgeon Dr. Gregory S. Keller described the new range as “…a huge step
International Stem Cell Corporation, a California-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. This patent is a key element of ISCO’s metabolic liver disease program and allows the Company to produce the necessary quantities of precursor cells in a more efficient and cost effective manner.
The patent, 8,268,621, adds to the Company’s growing portfolio of proprietary technologies relating to the development of potential treatments
UC Davis Health System researchers who are working to speed therapies to patients suffering from critical limb ischemia, osteoporosis and Huntington’s disease received approval today for three separate research grants from the state’s stem cell agency totaling more than $53 million. Each of the research studies that can now begin at UC Davis are specifically designed to lead to U.S. Food and Drug Administration approval of human clinical trials using stem cells and regenerative therapies.
At today’s meeting of the California Institute for Regenerative Medicine (CIRM) in San Francisco, the agency’s 29-member governing board approved five other grant
Researchers have reversed aging in old mice by injecting them with a longevity gene and rejuvenating their stem cells‘ regenerative potential.
The study by University of California-Berkeley biologists represents a major advance in understanding the molecular mechanisms behind aging, paving the way for the development of targeted treatments for age-related degenerative diseases.
The found that SIRT3, one among a class of proteins known as sirtuins, plays an important role in helping aged blood stem cells cope with stress, the journal Cell reports.
When they infused the blood stem cells of old mice with SIRT3, the treatment boosted the formation of new blood